An immunotherapy cocktail from Roche helped slow an aggressive type of breast cancer where new treatments have proven elusive.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
It’s not hard to see how precision medicine will re-make the world of research and development and manufacturing and distribution for pharmaceutical and medical product companies. But it will make new demands on the supply chains of these organizations.
Merrimack Pharmaceuticals’ stock plunged more than 32 percent after the company announced the termination of the SHERLOC Phase II clinical trial.
Boston-based Proteostasis Therapeutics announced positive preliminary data from the ongoing Phase I clinical trial of PTI-808 and PTI-801 in cystic fibrosis. Despite being an early-stage trial and preliminary data, company shares exploded upward by 301 percent, with more than 44 million shares trading hands.
Merck & Co.’s cancer drug Keytruda in combination with Pfizer Inc.’s Inlyta met the main goals of a late-stage study for the most common form of kidney cancer.
Eisai Co. and Purdue Pharma L.P. announced top-line results from the companies’ SUNRISE 2 Phase III clinical trial of lemborexant for sleep-wake disorders.
People with restless legs syndrome may be more likely to think about suicide or to actually make plans to take their own lives, compared to people without the condition, a new study suggests.
Drugmakers Sanofi and Regeneron received positive results for Dupixent, which treats eczema and is seen as a key driver of future revenues.
Bristol-Myers Squibb’s blockbuster cancer drug Opdivo failed to meet the main goal in a late-stage trial on patients with a type of lung cancer, whose condition had relapsed after chemotherapy.
Bristol-Myers Squibb and Israel’s Compugen will collaborate in clinical trials for patients with advanced solid tumors.
A post-hoc analysis of a Phase II sickle cell disease study showed that patients treated with Novartis’ experimental humanized anti-P-selectin monoclonal antibody crizanlizumab significantly reduced occurrences of vaso-occlusive crisis, a serious disease complication that can lead to organ failure.